TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Inclusion Criteria:

* Women between 22-36 weeks of pregnancy who are diagnosed with GDM
* A diagnosis of GDM during the current pregnancy by two or more 100g Oral Glucose Tolerance Test (OGTT) values exceeding established thresholds (fasting 95, 1h 180, 2h 155, 3h 140 mg/dL)
* Age 18-45 years old
* A pre-pregnancy body mass index \> 25kg/m2

  * Ability to read and write in English
  * Willingness to consent for themselves and their infant

Exclusion Criteria:

* They have a A1c ≥ 6.5 mg/dL (Type 2 diabetes)
B: Inclusion Criteria:

* Diagnosis of Gestational Diabetes Mellitus

Exclusion Criteria:

* Ever diagnosed with diabetes when not pregnant
* Ever diagnosed with cardiovascular disease
* Ever diagnosed with lung disease
* Hemoglobin \< 9.5 mg/dl
* Hematocrit less than 30%
* SBP \>= 140 or DBP \>= 90 in the last month
* Diagnosis of thyroid disease in the last month
C: Inclusion Criteria:

* Pregnant
* Gestational age at enrollment 24 - 31 weeks

Exclusion Criteria:

* Diabetes diagnosed prior to pregnancy
* Abnormal gestational diabetes (\>= 135 mg/dl) testing prior to 24 weeks' gestation
* Gestational diabetes in a previous pregnancy
* History of stillbirth or fetal death
* Pregnancy with more than one fetus
* Known major fetal anomaly
* Current or planned corticosteroid therapy
* Asthma requiring medication
* Current or planned beta adrenergic therapy
* Chronic hypertension requiring medication within 6 months of or during pregnancy
* Chronic medical conditions such as HIV/AIDS, kidney disease, or congenital heart disease
* Hematologic or autoimmune disease such as sickle cell disease, other hemoglobinopathies, lupus, or antiphospholipid syndrome
* Maternal or fetal conditions likely to require preterm delivery, such as pre-eclampsia, preterm labor, or intrauterine growth retardation
* Previous or planned tocolytic therapy to induce labor or increase contraction strength
D: Inclusion Criteria:

* All pregnant women who are diagnosed to have GDM.

Exclusion Criteria:

* Diagnosis of overt diabetes during OGTT;
* Younger than 18 years of age;
* Non-singleton pregnancy;
* Maternal-foetal ABO blood type incompatibility;
* Maternal diseases such as chronic hypertension,thyrotoxicosis, prepregnancy diabetes and use of long-term medications that may affect glucose metabolism.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants
Brief Summary: The purpose of this study is to determine whether a 14 week intervention is successful in improving outcomes for women with gestational diabetes mellitus and their infants.


Options:
A: Inclusion Criteria:

* Early childcare center must prepare and provide meals for lunch

Exclusion Criteria:

* Any early childcare center that has already received a physical activity or nutrition promoting intervention in the past to avoid underestimating the effect of the Healthy Start intervention
* For feasibility reasons, the number of children attending the early childcare center also serves as an exclusion criterion; centers with less than 20 children from the ages of 3 to 5 are not considered
B: Inclusion Criteria:

* Women between 22-36 weeks of pregnancy who are diagnosed with GDM
* A diagnosis of GDM during the current pregnancy by two or more 100g Oral Glucose Tolerance Test (OGTT) values exceeding established thresholds (fasting 95, 1h 180, 2h 155, 3h 140 mg/dL)
* Age 18-45 years old
* A pre-pregnancy body mass index \> 25kg/m2

  * Ability to read and write in English
  * Willingness to consent for themselves and their infant

Exclusion Criteria:

* They have a A1c ≥ 6.5 mg/dL (Type 2 diabetes)
C: Inclusion Criteria:

* Child age \< 60 months

Exclusion Criteria:

* None
D: Inclusion Criteria:

* one obese or two overweight parents, 1 year old child

Exclusion Criteria:

* weight effecting diseases

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Sustainable Financial Incentives To Improve Prescription Practices For Malaria
Brief Summary: This project aims to test an innovative, sustainable financial incentive designed to reduce the number of non-malarial fevers that are treated inappropriately with antimalarial drugs.


Options:
A: Inclusion Criteria:

* Mothers of infants 0-12 months residing in the catchment area of the subcenters

Exclusion Criteria:

-
B: Inclusion Criteria:

* Parent/caregiver receiving HIV care
* Parent/caregiver has one or more children \<13 years old
* Child is HIV exposed (parent/caregiver report or clinic confirmation)
* Caregiver reports child's HIV status is unknown

Exclusion Criteria:

* None

  * The investigators reserve the right to exclude any potential enrollee who is deemed to be at high personal risk, or whose children are at high personal risk, of interpersonal violence, by study participation .
C: Inclusion Criteria:

* Living in the catchment area of a health center under the study

Exclusion Criteria:

* Mother or tutor of the child not available for the survey
* Head of household or husband of the mother of the child not available for the survey
D: Inclusion Criteria:

* Health facility (level 3) in Western or Rift valley province, within the Academic Model Providing Access to Healthcare (AMPATH) catchment area
* Consent from Provincial Medical Officer of Health, District Medical Officer of Health and Health facility in-charge
* Functioning laboratory including microscopic diagnosis of malaria and at least one laboratory technician.

Exclusion Criteria:

* Lack of consent from any level
* Lack of adequate laboratory infrastructure or personnel

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Study of Surgical Methods for Keratoconus
Brief Summary: The purpose of this study is to determine which surgical method makes less corneal haze


Options:
A: Inclusion Criteria:

* Age between 16-40 years
* axial topography consistent with keratoconus
* minimum corneal thickness more than 400 µm and a progression of keratoconus in past 12 months

Exclusion Criteria:

* history of ocular herpes or non-healing corneal ulcers
* subjects with current ocular infection
* severe preoperative corneal haze or scar
* severe ocular surface disease
* autoimmune diseases
* pregnant women
B: Inclusion Criteria:

* Diagnosis of ectasia after refractive surgery
* Documented ectasia on Pentacam or topography map
* BSCVA worse than 20/20
* Must complete all study visits

Exclusion Criteria:

* History of delayed wound healing
* History of corneal melt or corneal dystrophy
C: Inclusion Criteria:

* Diagnosis of keratoconus
* Documented progression over previous 24 months
* Decreased BSCVA
* Must complete all study visits

Exclusion Criteria:

* Prior corneal surgery or Intacs
* History of delayed wound healing
D: Inclusion Criteria:

* Diagnosis of keratoconus with documented progression over the previous 12 months.
* Diagnosis of corneal ectasia
* Must be able to complete all study visits

Exclusion Criteria:

* Prior corneal surgery in the keratoconus group
* Corneal scarring

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Study of Surgical Methods for Keratoconus
Brief Summary: The purpose of this study is to determine which surgical method makes less corneal haze


Options:
A: Inclusion Criteria:

* progressive keratoconus stage 1-2

Exclusion Criteria:

* any concomitant ocular disease
B: Inclusion Criteria:

* Age between 16-40 years
* axial topography consistent with keratoconus
* minimum corneal thickness more than 400 µm and a progression of keratoconus in past 12 months

Exclusion Criteria:

* history of ocular herpes or non-healing corneal ulcers
* subjects with current ocular infection
* severe preoperative corneal haze or scar
* severe ocular surface disease
* autoimmune diseases
* pregnant women
C: Inclusion Criteria:

1. 10 years of age or older
2. Having documented ectasia on topography or tomography after previous refractive surgery OR progressive keratoconus defined as one or more of the following changes over a period of 36 months or less before randomization:

   1. An increase of ≥ 1.00 D in the steepest keratometry value (or sim K)
   2. An increase of ≥ 1.00 D in regular astigmatism evaluated by subjective manifest refraction
   3. A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective manifest refraction
   4. Documented decrease in visual acuity associated with irregular astigmatism and topographic features of ectasia.
3. Subjects with keratoconus diagnosis only:

   a. Axial topography consistent with keratoconus b. Presence of central or inferior steepening on the Pentacam map. c. Presence of one or more slit lamp findings associated with keratoconus, such as: i. Fleischer ring ii. Vogt striae iii. Corneal thinning iv. Corneal scarring
4. Contact Lens Wearers Only: Removal of contact lenses for the required period of time prior to the screening refraction:

   Contact Lens Type Minimum Discontinuation Time Soft 3 Days Soft Extended Wear 1 Week Soft Toric 2 Weeks Rigid gas permeable 2 Weeks
5. Signed written informed consent

Exclusion Criteria:

* 1. Any keratoconus patient over 21 years of age without evidence of progression of his corneal deformity.

  2. Patients with excessively thin corneas. 3. Previous ocular condition in the eyes to be treated that may predispose the eye for future complications, for example:

  a. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) b. Clinically significant corneal scarring in the proposed treatment zone 4. A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.

  5. A known sensitivity to treatment medications. 6. Patients with a current condition that, in the treating physician's opinion, would interfere with or prolong epithelial healing.

  7. Pregnancy (including plan to become pregnant) or lactation during the course of the study
D: Inclusion Criteria:

* Age 10-70, willing to participate, diagnosis of corneal ectasia disorder

Exclusion Criteria:

* Unwilling or unable to participate in trial

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Integrated Collaborative Care for Substance Use Disorders
Brief Summary: Primary care settings (PCS) are a missed opportunity for delivering evidence-based treatments for opiate and alcohol-use disorders (OAUD). The investigators propose to evaluate the costs and effectiveness of two strategies to increase the delivery of OAUD treatments in PCS, integrated collaborative care (ICC) and education and resources (E\&R). The investigators hypothesize that ICC will be more effective than E\&R in promoting A. Implementation outcomes B. Service system outcomes and C. Patient outcomes.

Results from our study will help providers choose between two different strategies and advance the field of implementation research.


Options:
A: Inclusion Criteria:

1. Must be self-identified as born female
2. Must be able to be provide written informed consent
3. Must be able to speak and understand English as determined by staff during recruitment
4. Must be 13-45 years old at time of consent
5. Must have been seen for a patient visit in one of the three implementation clinics during the preceding 60 days and identified as a PrEP candidate based on point-of-care HIV testing and risk assessment

Exclusion Criteria:

1. HIV-infected at the time of screening by self-report or screening laboratory assessment
2. Currently enrolled in an HIV vaccine trial
3. Has any condition that in the opinion of study staff would make participation in the study unsafe or interfere with achieving study objectives
4. Has been on PrEP for 7 or more consecutive days in the past
5. Currently receiving PrEP services at any location outside the 3 implementation clinics
6. Currently participating in another PrEP or candidate PrEP study
B: Inclusion Criteria:

* adults ≥18 years old
* have been diagnosed with controlled or uncontrolled diabetes

Exclusion Criteria:

* \< than 18 years of age
* not diagnosed with diabetes
C: Inclusion Criteria:

* Attendance at ANC clinic in a primary care facility in Kakamega north

Exclusion Criteria:

* Gestational age \< 16 weeks,
* Gestational age \> 30 weeks,
* Dietary or medicinal consumption of adequate calcium (according to the screening survey),
* Intention to leave study community before 8weeks from date of interview
D: Inclusion Criteria:

* opiate or alcohol use disorder
* not currently in substance use disorder treatment
* past 30 day use of alcohol or opioids
* English or Spanish speaking

Exclusion Criteria:

* co-morbid severe mental illness
* medically unstable

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Integrated Collaborative Care for Substance Use Disorders
Brief Summary: Primary care settings (PCS) are a missed opportunity for delivering evidence-based treatments for opiate and alcohol-use disorders (OAUD). The investigators propose to evaluate the costs and effectiveness of two strategies to increase the delivery of OAUD treatments in PCS, integrated collaborative care (ICC) and education and resources (E\&R). The investigators hypothesize that ICC will be more effective than E\&R in promoting A. Implementation outcomes B. Service system outcomes and C. Patient outcomes.

Results from our study will help providers choose between two different strategies and advance the field of implementation research.


Options:
A: Inclusion Criteria:

* Attendance at ANC clinic in a primary care facility in Kakamega north

Exclusion Criteria:

* Gestational age \< 16 weeks,
* Gestational age \> 30 weeks,
* Dietary or medicinal consumption of adequate calcium (according to the screening survey),
* Intention to leave study community before 8weeks from date of interview
B: Inclusion Criteria:

1. Must be self-identified as born female
2. Must be able to be provide written informed consent
3. Must be able to speak and understand English as determined by staff during recruitment
4. Must be 13-45 years old at time of consent
5. Must have been seen for a patient visit in one of the three implementation clinics during the preceding 60 days and identified as a PrEP candidate based on point-of-care HIV testing and risk assessment

Exclusion Criteria:

1. HIV-infected at the time of screening by self-report or screening laboratory assessment
2. Currently enrolled in an HIV vaccine trial
3. Has any condition that in the opinion of study staff would make participation in the study unsafe or interfere with achieving study objectives
4. Has been on PrEP for 7 or more consecutive days in the past
5. Currently receiving PrEP services at any location outside the 3 implementation clinics
6. Currently participating in another PrEP or candidate PrEP study
C: Inclusion Criteria:

* adults ≥18 years old
* have been diagnosed with controlled or uncontrolled diabetes

Exclusion Criteria:

* \< than 18 years of age
* not diagnosed with diabetes
D: Inclusion Criteria:

* opiate or alcohol use disorder
* not currently in substance use disorder treatment
* past 30 day use of alcohol or opioids
* English or Spanish speaking

Exclusion Criteria:

* co-morbid severe mental illness
* medically unstable

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Integrated Collaborative Care for Substance Use Disorders
Brief Summary: Primary care settings (PCS) are a missed opportunity for delivering evidence-based treatments for opiate and alcohol-use disorders (OAUD). The investigators propose to evaluate the costs and effectiveness of two strategies to increase the delivery of OAUD treatments in PCS, integrated collaborative care (ICC) and education and resources (E\&R). The investigators hypothesize that ICC will be more effective than E\&R in promoting A. Implementation outcomes B. Service system outcomes and C. Patient outcomes.

Results from our study will help providers choose between two different strategies and advance the field of implementation research.


Options:
A: Inclusion Criteria:

* opioid dependence

Exclusion Criteria:

* current dependence on alcohol, cocaine, benzodiazepines or sedatives
* current suicide or homicide risk
* current psychotic disorder or untreated major depression
* inability to read or understand English
* life-threatening or unstable medical problems
B: Inclusion Criteria:

* Opioid dependence (DSM-IV TR)
* Age 18 or above
* Applied \& Approved for Norway's national OMT program
* Discharge within 30 days of inclusion from a controlled environment; e.g. inpatient treatment or correctional (prison) facility
* Voluntarily seeking treatment for opioid dependence

Exclusion Criteria:

* Pregnant or breast-feeding
* Acute or recurring severe psychiatric disorder, e.g. psychosis, suicidality
* Serious debilitation of liver or renal function (e.g. Child-Pugh level C)
* Use of excluded medication
* Known intolerance to study drugs or their ingredients
* Employment in firm manufacturing one of the study drugs or close relation to such person
C: Inclusion Criteria:

* opiate or alcohol use disorder
* not currently in substance use disorder treatment
* past 30 day use of alcohol or opioids
* English or Spanish speaking

Exclusion Criteria:

* co-morbid severe mental illness
* medically unstable
D: Inclusion Criteria:

* HIV-infected
* Clinical Diagnosis of Opioid Dependence
* Fluent in Bahasa Malaysia or English
* Within 90 to 180 days of release from prison
* Planning to live in Klang Valley region after release from prison
* Able to provide informed consent

Exclusion Criteria:

* Pregnancy or planning to become pregnant (female only)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Integrated Collaborative Care for Substance Use Disorders
Brief Summary: Primary care settings (PCS) are a missed opportunity for delivering evidence-based treatments for opiate and alcohol-use disorders (OAUD). The investigators propose to evaluate the costs and effectiveness of two strategies to increase the delivery of OAUD treatments in PCS, integrated collaborative care (ICC) and education and resources (E\&R). The investigators hypothesize that ICC will be more effective than E\&R in promoting A. Implementation outcomes B. Service system outcomes and C. Patient outcomes.

Results from our study will help providers choose between two different strategies and advance the field of implementation research.


Options:
A: Patient Inclusion Criteria:

* Currently a patient within Wishard Health Services in Central Indiana
* Diagnosed with possible or probable Alzheimer's Disease
* Age 45 or older
* English speaking
* Hear well enough to answer questions in person or by telephone
* Community-dwelling (includes senior communities, but not skilled nursing facilities)
* Caregiver willing to participate in the study
* Willing to receive home visits
* Lives in Indianapolis metro area and planning to continue care at primary care clinic

Caregiver Inclusion Criteria

* Age 18 or older
* English speaking
* Hear well enough to answer questions in person or by telephone
* Community-dwelling
* Willing to receive home visits

Exclusion Criteria:

* Not a current patient within Wishard Health Services
* Does not speak English
* Currently enrolled in another study
* Non-community dwelling, or residing in a skilled nursing facility
B: Inclusion Criteria:

* Enrolled as a pt in the VA Healthcare System
* screens positive for major depression
* has a scheduled visit at a primary care site taking part in the study

Exclusion Criteria:

* severe alcohol abuse
* psychosis
* dementia
* acutely suicidal (at screening)
* lack of access to or ability to use a phone
C: Inclusion Criteria:

* opiate or alcohol use disorder
* not currently in substance use disorder treatment
* past 30 day use of alcohol or opioids
* English or Spanish speaking

Exclusion Criteria:

* co-morbid severe mental illness
* medically unstable
D: Inclusion Criteria:

* Diagnosis of diabetes and/or heart disease
* Poor disease control (defined as an HbA1c level of at least 8.5%, blood pressure greater than 140/90 mm Hg, LDL cholesterol greater than 130 mg/dL)
* Diagnosis of major depressive disorder

Exclusion Criteria:

* History of psychosis
* At high risk for suicide
* Cognitive impairment
* Current alcohol or substance abuse disorder
* Does not own a telephone
* Currently seeking psychiatric care
* Pregnant or breastfeeding
* Currently enrolled in a Group Health Cooperative disease management program
* Terminal illness
* Plans to leave Group Health Cooperative in less than a year
* Does not speak English

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The "START" (a Streamlined ART Initiation Strategy) Study
Brief Summary: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2) targeted knowledge transfer (i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3) feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.


Options:
A: Inclusion Criteria:

Hospital inclusion criteria:

1. An Ontario hospital with a procedure volume of 15 or more major rectal cancer resections per year for fiscal years 1996 to 1998.

Patient inclusion criteria:

1. Consecutive patients at each participating site who underwent major rectal cancer surgery.
2. Tumor located within 15 cm of anal verge by rigid sigmoidoscopy, or, at or below the level of the sacral promontory at the time of surgery.

Exclusion Criteria:

-
B: Inclusion Criteria:

The following patients will be eligible for study participation:

* Patients with either type 1 or type 2 diabetes. Diabetes will be defined as those patients presently taking either oral hypoglycemic agents or insulin therapy (oral hypoglycemic agents to include all drugs in the drug classes of: alpha-glucosidase inhibitors, biguanides, meglitinides, sulfonylureas, thiazolidinediones and adjunctive therapy) taken for \>6 months to rule-out steroid-induced diabetes and gestational diabetes.

Exclusion Criteria:

Patients will be excluded from the study if they:

* Do not provide or are unable to provide written informed consent
* Refuse or are unlikely to attend follow-up visits for BP measurements
* Are institutionalized
* Are \<18 years of age
* Do not understand English
* Enrolled in other diabetes or hypertension trials

Subjects will be recruited whether or not they are receiving antihypertensive therapy.
C: Inclusion Criteria:

* All MJAP-supported clinics in Kampala and Mbarara Districts

Exclusion Criteria:

* None.
D: Inclusion Criteria:

- Physicians of primary care unit with at least four family physicians

Exclusion Criteria:

* Physicians who are planning to retire within two years
* Physicians without an assigned patient list
* Physicians with an incomplete patient list

Answer: C